Montréal 2022 motto: Back to our future… AD in childhood
Back to our future… AD in childhood
All presentations are available for registered attendees in the app. from the meeting:
Credentials have been sent to all attendees by email on October 14, 2022:
➜ “Welcome Montreal! Download your ISAD Event App” by Pheedloop
| Time (EDTUTC) |
Monday, October 17th, 2022 |
|
|---|---|---|
ISAD Pre-Meeting |
||
| 08:00 – 11:30 12:00 – 15:30 | Organization of Care in Atopic Dermatitis➜ more information Bridging the Gaps |
|
| 11:30 – 13:00 15:30 – 17:00 | Lunch | |
Opening Welcome |
||
| 13:00 – 13:30 17:00 – 17:30 | Welcome Address Danielle MARCOUX, Michele RAMIEN ISAD Board Welcome Alain TAIEB |
|
Plenary Session 1: Keynote — Atopic Dermatitis in Children |
||
| 13:30 – 14:30 17:30 – 18:30 | Moderators: Danielle MARCOUX + Michele RAMIEN Keynote Speakers: Danielle MARCOUX, Montreal, QC + Amy PALLER, Chicago, IL |
|
| 13:30 17:30 — 45 min | IL.1 | Milestones in the History of Atopic Dermatitis Daniel WALLACH |
| IL.2 | Today and in Canada Danielle MARCOUX |
|
| IL.3 | The future in pediatrics Amy PALLER |
|
| 14:30 – 15:15 18:30 – 19:15 | Refreshment break in the Exhibit Hall | |
Scientific Session 2: Outcome measures, primary prevention & diagnosis |
||
| 15:15 – 16:50 19:15 – 20:50 | Moderators: Aaron DRUCKER + Amy PALLER | |
| 15:15 19:15 — 5 min | Introduction of session | |
| 15:20 19:20 — 20 min | IL.4 | HOME update, prevention update and diagnostic conundrums Eric SIMPSON |
| 15:40 19:40 — 10 min | OL.1 | Emollients for atopic dermatitis prevention: 5-year results from the BEEP Randomised Trial Hywel WILLIAMS |
| 15:50 19:50 — 10 min | OL.2 | Remote severity assessment in atopic dermatitis: validity and reliability of the remote EASI and SA-EASI Aviël RAGAMIN |
| 16:00 20:00 — 10 min | OL.3 | Atopic dermatitis: factors associated with age of onset in adulthood versus childhood Laura MAINTZ |
| 16:10 20:10 — 10 min | OL.4 | Validating the use of RECAP of atopic eczema (RECAP) instrument to measure eczema control of adult patients in an Asian clinical setting Yik Weng YEW |
| 16:20 20:20 — 10 min | OL.5 | Prevalence, clinical features, and risk factors of severity of atopic dermatitis in children with skin phototype Ⅵ in Senegal Birame SECK |
| 16:30 20:30 — 10 min | OL.6 | The burden of stigma in pediatric Atopic Dermatitis: measurement using the new, validated PROMIS pediatric stigma and skin module Amy PALLER |
| 16:40 20:40 — 10 min | Summary and unmet needs Aaron DRUCKER + Amy PALLER + Eric SIMPSON |
|
| 17:15 – 17:45 21:15 – 21:45 | e-Poster Presentation 1 and Visit Exhibits | |
| 17:00 – 19:00 21:00 – 23:00 | ISAD Board meeting | |
| 18:00 – 20:00 22:00 – 24:00 | Welcome Reception in Exhibit Hall | |
| Time (EDTUTC) |
Tuesday, October 18th, 2022 |
|
|---|---|---|
| 07:45 – 09:00 11:45 – 13:00 | Continental Breakfast | |
| 08:15 – 08:45 12:15 – 12:45 | e-Poster Presentation 2 | |
Scientific Session 3: Mechanisms of disease & models |
||
| 09:00 – 10:35 13:00 – 14:35 | Moderators: Kirk BARBER + Chih-ho HONG | |
| 09:00 13:00 — 5 min | Introduction of session | |
| 09:05 13:05 — 20 min | IL.5 | The exposome in atopic dermatitis Carsten FLOHR |
| 09:25 13:25 — 10 min | OL.7 | Direct Experimental Evidence Establishing Staphylococcus aureus Superantigens Drive Atopic March from Atopic Dermatitis to Asthma Govindarajan RAJAGOPALAN |
| 09:35 13:35 — 10 min | OL.8 | Diagnosis and Management of Pediatric Chronic Hand Eczema: The PEDRA CACHES Survey Michael HAFT |
| 09:45 13:45 — 10 min | OL.9 | IgE-mediated autoimmunity in atopic dermatitis associates with atopic disorders and is influenced by environmental and life style factors Inge KORTEKAAS KROHN |
| 09:55 13:55 — 10 min | OL.10 | Distinct IL-13 production and accumulation in lesional and non-lesional skin of atopic dermatitis patients Gaurav ISOLA |
| 10:05 14:05 — 10 min | OL.11 | Aero-allergen exposure in the house is associated with atopic dermatitis in children from urban, rural, and peri-urban areas of South Africa Janine DEWAR |
| 10:15 14:15 — 10 min | OL.12 | Antimicrobial and anti-inflammatory effects of vernix caseosa on the epidermal barrier of atopic dermatitis models Carolina CABALÍN |
| 10:25 14:25 — 10 min | Summary and unmet needs Kirk BARBER + Carsten FLOHR + Chih-ho HONG |
|
| 10:35 – 11:05 14:35 – 15:05 | Refreshment Break and Visit Exhibits | |
Scientific Session 4: The Canadian Experience (outreach/research) |
||
| 11:05 – 12:10 15:05 – 16:10 | Moderators: Rachel ASINIWASIS + Robert BISSONNETTE | |
| 11:05 15:05 — 5 min | Introduction of session | |
| 11:10 15:10 — 20 min | IL.6 | Infant trajectories to atopic disease Padmaja SUBBARAO |
| 11:30 15:30 — 10 min | IL.7 | The McGill University Hospital Center for Adult Atopic Dermatitis: Patient-oriented research Carolyn JACK |
| 11:40 15:40 — 10 min | OL.13 | Development of “Living with eczema”, an educational animated video for children with moderate to severe atopic dermatitis aiming at reducing disease burden Danielle MARCOUX |
| 11:50 15:50 — 10 min | IL.8 | Atopic Dermatitis in Canadian Indigenous Peoples: results from a systematic scoping review on indigenous skin disease in North America Rachel ASINIWASIS |
| 12:00 16:00 — 10 min | Summary and unmet needs Rachel ASINIWASIS + Robert BISSONNETTE + Padmaja SUBBARAO |
|
| 12:10 – 13:50 16:10 – 17:50 | Lunch and Visit Exhibits | |
| 13:00 – 13:30 17:00 – 17:30 | e-Poster Presentation 3 | |
Scientific Session 5: Itch and Pain / Therapeutic Patient Education |
||
| 13:50 – 15:05 17:50 – 19:05 | Moderators: Natalie CUNNINGHAM + Sunil KALIA | |
| 13:50 17:50 — 5 min | Introduction of session | |
| 13:55 17:55 — 20 min | IL.9 | Itch and pain: Unraveling the symptomatic burden of atopic dermatitis Raj CHOVATIYA |
| 14:15 18:15 — 10 min | OL.14 | Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli Madison MACK |
| 14:25 18:25 — 10 min | OL.15 | Efficacy and sustainability of a four-hour structured compact patient education program for atopic dermatitis patients – A prospective monocentric trial Teodora PUMNEA |
| 14:35 18:35 — 10 min | OL.16 | Results of two online randomised controlled trials of the Eczema Care Online intervention for parents/carers of children and young people with eczema Kim THOMAS |
| 14:45 18:45 — 10 min | OL.17 | Functional somatosensory adaptation to acute stress is diminished in atopic dermatitis Macarena TEJOS-BRAVO |
| 14:55 18:55 — 10 min | Summary and unmet needs Raj CHOVATIYA + Natalie CUNNINGHAM + Sunil KALIA |
|
| 15:05 – 15:35 19:05 – 19:35 | Refreshment break in the Exhibit Hall | |
Scientific Session 6: Quality of Life & Comorbidities |
||
| 15:35 – 16:30 19:35 – 20:30 | Moderators: Philippe BEGIN + Marissa JOSEPH | |
| 15:35 19:35 — 5 min | Introduction of session | |
| 15:40 19:40 — 20 min | IL.10 | How might evolving therapies for atopic dermatitis change comorbidities and perspectives on quality-of-life impact and outcomes? Lawrence EICHENFIELD |
| 16:00 20:00 — 10 min | OL.18 | The impact of systemic treatment of atopic dermatitis on depressive symptoms: a prospective clinical cohort study Lina IVERT |
| 16:10 20:10 — 10 min | OL.19 | Patients’ and caregivers’ experiences with atopic dermatitis-related burden, medical care, and treatments in 8 countries Korey CAPOZZA |
| 16:20 20:30 — 10 min | Summary and unmet needs Philippe BEGIN + Lawrence EICHENFIELD + Marissa JOSEPH |
|
Plenary Session 7: Building global Atopic Dermatitis awareness |
||
| 16:35 – 17:10 20:35 – 21:10 | Moderator: Rachel ASINIWASIS | |
| 16:35 20:35 — 5 min | Introduction of session | |
| 16:40 20:40 — 20 min | IL.11 | How to include atopic dermatitis and common chronic skin diseases within the WHO strategic framework for the integrated control and management of skin NTDs Alain TAIEB |
| 17:00 21:00 — 10 min | Q&A discussion Rachel ASINIWASIS + Alain TAIEB |
|
| 19:00 – 22:00 23:00 – 02:00 | GALA Dinner and Rajka Award: Le Windsor Ballrooms (offsite) Presentation of RAJKA Medals by Mrs Susanne RAJKA to the two awardees (2020 + 2022). |
|
| Time (EDTUTC) |
Wednesday, October 19th, 2022 |
|
|---|---|---|
| 07:45 – 09:00 11:45 – 13:00 | Continental Breakfast | |
| 08:15 – 08:45 12:15 – 12:45 | e-Poster Presentation 4 | |
Scientific Session 8: Technology and AD |
||
| 09:00 – 10:35 13:00 – 14:35 | Moderators: Joseph LAM + Miriam WEINSTEIN | |
| 09:00 13:00 — 5 min | Introduction of session | |
| 09:05 13:05 — 20 min | IL.12 | Specific considerations when using teledermatology to diagnose and manage atopic dermatitis Trevor CHAMPAGNE |
| 09:25 13:25 — 10 min | OL.20 | Recency bias in weekly POEM recording and its effects on POEM prediction Ariane DUVERDIER |
| 09:35 13:35 — 10 min | OL.21 | Fully automated assessment of Atopic Dermatitis severity from real-world digital images Reiko TANAKA |
| 09:45 13:45 — 10 min | OL.22 | Personalised predictions of atopic dermatitis severity dynamics and treatment recommendations using a Bayesian machine learning approach Reiko TANAKA |
| 09:55 13:55 — 10 min | OL.23 | Skin testing to determine Atopic Dermatitis risk: an observational birth cohort study John CHITTOCK |
| 10:05 14:05 — 10 min | OL.24 | Feasibility of a Digital Therapeutic for Patients With Atopic Dermatitis: Analysis of Engagement, Retention and Acceptability Sigríður L. GUÐMUNDSDÓTTI |
| 10:15 14:15 — 10 min | OL.25 | Assessing properties of eczema skin with spectroscopy Sunil KALIA |
| 10:25 14:25 — 10 min | Summary and unmet needs Joseph LAM + Trevor CHAMPAGNE + Miriam WEINSTEIN |
|
| 10:35 – 11:05 14:35 – 15:05 | Refreshment break in the Exhibit Hall | |
Scientific Session 9: ISAD Fellow Research |
||
| 11:05 – 11:40 15:05 – 15:40 | Moderators: Michele RAMIEN + Kenji KABASHIMA + Peter SCHMID-GRENDELMEIER | |
| 11:05 15:05 — 5 min | Introduction of session | |
| 11:10 15:10 — 10 min | OL.26 | Improvement of the global management of Atopic Dermatitis by Teledermatology in peripheral health centres in Togo (TeleAD) Julienne TECLESSOU |
| 11:20 15:20 — 10 min | IL.13 | Leaning on epidemiology and evidence-based medicine during the translational revolution Aaron DRUCKER |
| 11:30 15:30 — 10 min | Summary and unmet needs Michele RAMIEN + Kenji KABASHIMA + Peter SCHMID-GRENDELMEIER |
|
Scientific Session 10: Novel and targeted management of AD – part 1 |
||
| 11:45 – 12:20 15:45 – 16:20 | Moderator: Melinda GOODERHAM + Johannes RING | |
| 11:45 15:45 — 5 min | Introduction of session | |
| 11:50 15:50 — 20 min | IL.14 | Therapeutic agents for atopic dermatitis in 2022 and beyond Andreas WOLLENBERG |
| 12:10 16:10 — 10 min | OL.36 | Dupilumab inhibits expression of fibronectin and fibrinogen, skin proteins that regulate Staphylococcus Aureus adhesion to atopic dermatitis skin Elena GOLEVA |
| 12:20 – 13:10 16:20 – 17:10 | Lunch and Visit Exhibits | |
Scientific Session 10: Novel and targeted management of AD – part 2 |
||
| 13:10 – 14:55 17:10 – 18:55 | Moderator: Melinda GOODERHAM + Johannes RING | |
| 13:10 17:10 — 5 min | Introduction to part 2 | |
| 13:15 17:15 — 10 min | OL.27 | A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate versus ciclosporin in the treatment of severe atopic eczema in children: The TREatment of severe Atopic eczema Trial (TREAT) Carsten FLOHR |
| 13:25 17:25 — 10 min | OL.28 | The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: results from the global SECURE-AD registry Conor BRODERICK |
| 13:35 17:35 — 10 min | OL.29 | Clinical and histopathological characterization of atypical lymphoid reactions in patients with atopic dermatitis treated with new advanced systemic therapies Celeste BOESJES |
| 13:45 17:45 — 10 min | OL.30 | The pathogenesis and course of ocular surface disease during dupilumab treatment in atopic dermatitis patients Roselie ACHTEN |
| 13:55 17:55 — 10 min | OL.31 | Living network meta-analysis of systemic treatments for atopic dermatitis Aaron DRUCKER |
| 14:05 18:05 — 10 min | OL.32 | Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Lotte SPEKHORST |
| 14:15 18:15 — 10 min | OL.33 | Recapture of response with tralokinumab every second week in patients with moderate to severe atopic dermatitis relapsing after a step down to every 4 week dosing Eric SIMPSON |
| 14:25 18:25 — 10 min | OL.34 | Amlitelimab reduces serum IL-13 in a phase 2A clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay Michael CORK |
| 14:35 18:35 — 10 min | OL.35 | Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: results from a multicenter, randomized, double-blind, placebo-controlled phase 2B trial in China Jianzhong ZHANG |
| 14:45 18:45 — 10 min | Summary and unmet needs Melinda GOODERHAM + Andreas WOLLENBERG + Johannes RING |
|
Closing Remarks |
||
| 14:55 – 15:30 18:55 – 19:30 | Moderators: Danielle MARCOUX + Michele RAMIEN | |
| 14:55 18:55 — 15 min | ISAD, IEC, Opened, IPSD/ESPD/SPD, Patients | |
| 15:10 19:10 — 20 min | ISAD 2022 Closing Remarks Danielle MARCOUX + Michele RAMIEN |
|